Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.7455
+0.0249 (3.46%)
At close: Jun 18, 2025, 4:00 PM
0.7320
-0.0135 (-1.81%)
After-hours: Jun 18, 2025, 5:48 PM EDT
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $1.26M in the quarter ending March 31, 2025, with 11.68% growth. This brings the company's revenue in the last twelve months to $31.21M, up 1,251.21% year-over-year. In the year 2024, Lexicon Pharmaceuticals had annual revenue of $31.08M with 2,481.48% growth.
Revenue (ttm)
$31.21M
Revenue Growth
+1,251.21%
P/S Ratio
8.34
Revenue / Employee
$303,039
Employees
103
Market Cap
270.75M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 31.08M | 29.88M | 2,481.48% |
Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
LXRX News
- 10 hours ago - Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) - GlobeNewsWire
- 20 days ago - Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference - GlobeNewsWire
- 6 weeks ago - Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - GlobeNewsWire
- 7 weeks ago - Top 2 Health Care Stocks That May Crash This Month - Benzinga